Details for Patent: 8,969,355
✉ Email this page to a colleague
Which drugs does patent 8,969,355 protect, and when does it expire?
Patent 8,969,355 protects TRINTELLIX and is included in one NDA.
Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-two patent family members in thirty-four countries.
Summary for Patent: 8,969,355
Title: | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Abstract: | This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine. |
Inventor(s): | Bang-Andersen; Benny (Copenhagen S, DK), Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK) |
Assignee: | H. Lundbeck A/S (Valby, DK) |
Application Number: | 14/480,949 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,969,355 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,969,355
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,969,355
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Denmark | 2006 00824 | Jun 16, 2006 |
Denmark | 2006 01223 | Sep 22, 2006 |
Denmark | 2006 01384 | Oct 25, 2006 |
International Family Members for US Patent 8,969,355
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 061481 | ⤷ Try a Trial | |||
Argentina | 065797 | ⤷ Try a Trial | |||
Austria | E495745 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |